These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 1617626

  • 1. Adriamycin-induced modulation of host defenses in tumor-bearing mice.
    Maccubbin DL, Wing KR, Mace KF, Ho RL, Ehrke MJ, Mihich E.
    Cancer Res; 1992 Jul 01; 52(13):3572-6. PubMed ID: 1617626
    [Abstract] [Full Text] [Related]

  • 2. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
    Ho RL, Maccubbin DL, Ujházy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ.
    Oncol Res; 1993 Jul 01; 5(9):363-72. PubMed ID: 8038457
    [Abstract] [Full Text] [Related]

  • 3. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
    Maccubbin DL, Mace KF, Ehrke MJ, Mihich E.
    Cancer Res; 1989 Aug 01; 49(15):4216-24. PubMed ID: 2525950
    [Abstract] [Full Text] [Related]

  • 4. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
    Dong LF, Mei HS, Song SX, Lu ZJ.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May 01; 21(3):296-300. PubMed ID: 15862144
    [Abstract] [Full Text] [Related]

  • 5. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.
    Ehrke MJ, Verstovsek S, Ujházy P, Meer JM, Eppolito C, Maccubbin DL, Mihich E.
    Cancer Immunol Immunother; 1998 Feb 01; 45(6):287-98. PubMed ID: 9490198
    [Abstract] [Full Text] [Related]

  • 6. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin.
    Mace K, Mayhew E, Mihich E, Ehrke MJ.
    Cancer Res; 1988 Jan 01; 48(1):130-6. PubMed ID: 3257160
    [Abstract] [Full Text] [Related]

  • 7. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
    Ho RL, Maccubbin D, Zaleskis G, Krawczyk C, Wing K, Mihich E, Ehrke MJ.
    Oncol Res; 1993 Jan 01; 5(9):373-81. PubMed ID: 8038458
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC, Chikkala NF, Lewis I, Grabowski DR, Finke JH, Ganapathi R.
    Anticancer Res; 1992 Jan 01; 12(3):921-5. PubMed ID: 1622150
    [Abstract] [Full Text] [Related]

  • 9. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 10. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, Zanovello P.
    Cancer Res; 2000 Jun 15; 60(12):3232-8. PubMed ID: 10866316
    [Abstract] [Full Text] [Related]

  • 11. Effects of adriamycin on the activity of mouse natural killer cells.
    Santoni A, Riccardi C, Sorci V, Herberman RB.
    J Immunol; 1980 May 15; 124(5):2329-35. PubMed ID: 6444969
    [Abstract] [Full Text] [Related]

  • 12. [Anti-tumor effect of monkshood polysaccharide with adriamycin long circulating temperature-sensitive liposome and its mechanism].
    Dong LF, Zhang YJ, Liu JS, Song SX, Hou J, Lu ZJ.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul 15; 22(4):458-62. PubMed ID: 16806008
    [Abstract] [Full Text] [Related]

  • 13. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
    Zaleskis G, Ho RL, Diegelman P, Maccubbin D, Ujházy P, Mihich E, Ehrke MJ.
    Oncol Res; 1994 Jul 15; 6(4-5):183-94. PubMed ID: 7841541
    [Abstract] [Full Text] [Related]

  • 14. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M, Komeshima N, Nakajima S, Tsuruo T.
    Cancer Res; 1988 Dec 01; 48(23):6653-7. PubMed ID: 3180075
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov 01; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 16. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes.
    Yachi K, Suzuki N, Tanaka N, Okada K, Mitsui I, Kawato Y, Komagata Y, Komiyama K, Kikuchi H.
    Biopharm Drug Dispos; 1996 Nov 01; 17(8):699-715. PubMed ID: 8950048
    [Abstract] [Full Text] [Related]

  • 17. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr 01; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
    Gautam SC, Chikkala NF, Ganapathi R, Hamilton TA.
    Cancer Res; 1991 Nov 15; 51(22):6133-7. PubMed ID: 1682042
    [Abstract] [Full Text] [Related]

  • 19. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture.
    Ehrke MJ, Ryoyama K, Cohen SA.
    Cancer Res; 1984 Jun 15; 44(6):2497-504. PubMed ID: 6426781
    [Abstract] [Full Text] [Related]

  • 20. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A, Nowicky JW.
    Drugs Exp Clin Res; 1996 Jun 15; 22(3-5):103-13. PubMed ID: 8899312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.